Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Cash & Equivalents data on file, last reported at $32.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 53.91% year-over-year to $32.7 million; the trailing twelve-month figure through Dec 2025 stood at $32.7 million (down 53.91% YoY), and the FY2025 full-year result was $32.7 million, down 53.91% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $32.7 million, down from $75.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $164.7 million in Q2 2021 and bottomed at $32.7 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $81.0 million (2024), against an average of $90.3 million.
• The widest annual swing landed in 2021, when Cash & Equivalents plunged 99.87%; it then decreased 1.15% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $118.7 million in 2021, then declined by 27.6% to $85.9 million in 2022, then slipped by 11.59% to $76.0 million in 2023, then slipped by 6.6% to $71.0 million in 2024, then tumbled by 53.91% to $32.7 million in 2025.
• The last three Cash & Equivalents figures came in at $32.7 million (Q4 2025), $75.2 million (Q2 2025), and $71.0 million (Q4 2024), per Business Quant data.

Peer Comparison